Advances of CLDN18.2 protein in the therapy of malignant tumors
10.3969/j.issn.1000-8179.2019.06.223
- VernacularTitle:CLDN18.2蛋白在恶性肿瘤治疗中的研究进展*
- Author:
Liang'e XU
1
;
Tianyang HE
;
Li ZHANG
;
Yidan LU
;
Cong LUO
Author Information
1. ①浙江中医药大学(杭州市310053)
- Keywords:
CLDN18.2;
malignant tumors;
targeted therapy;
claudiximab (zolbetuximab/IMAB362)
- From:
Chinese Journal of Clinical Oncology
2019;46(6):311-315
- CountryChina
- Language:Chinese
-
Abstract:
With the development of molecular biology research, targeted therapy has become the fourth effective method for the treatment of malignant tumors after surgery, radiotherapy, and chemotherapy. Unlike the traditional chemotherapeutic drugs, molecular targeted drugs possess the advantages of high specificity, definite curative effects, and less adverse effects. CLDN18.2 protein is a transmembrane protein that is highly selective and stably overexpressed during the development of various malignant tumors, especially gastrointestinal tumors, and metastases. A specific antibody against this protein, claudiximab (zolbetuximab/IMAB362), has achieved great success in recent clinical trials. Thus, CLDN18.2 protein is expected to be a safe and effective molecular target for targeted therapy in some malignancies.
